Prevention of Rabies With Four Doses of Rabies Vaccine

Rabies Human Clinical Trial

Official title: Randomized, Blind and Positive Control Design: a Phase III Clinical Trial to Evaluate the Consistency Between Batches of 5 Doses of Freeze-dried Rabies Vaccine (Vero Cell) and the Immunogenicity and Safety of 4 Doses of Vaccine (1-1-1-1)

Status Enrolling by invitation

Clinical Trial Summary

To evaluate the non inferiority of the immunogenicity of the test vaccine inoculated according to the four dose immunization program over the five dose immunization program and the batches consistency of immunogenicity according to five dose immunization procedures.

Clinical Trial Description

• In the population aged 10-60 years, evaluate the non inferiority of the immunogenicity of the test vaccine inoculated according to the four dose immunization program (0, 3, 7, 14/28 days) over the five dose immunization program (0, 3, 7, 14, 28 days)；

• To evaluate the consistency of immunogenicity between batches of freeze-dried human rabies vaccine (Vero cell) inoculated according to five dose immunization procedures (0, 3, 7, 14, 28 days). ;

Related Conditions & MeSH terms

• Rabies
• Rabies Human

• NCT number: NCT05545371
• Study type: Interventional
• Source: Changchun Zhuoyi Biological Co., Ltd
• Status: Enrolling by invitation
• Phase: Phase 3
• Start date: June 18, 2022
• Completion date: December 30, 2024